Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group
about
Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in ChildrenImmunologic Changes Implicated in the Pathogenesis of Focal Segmental GlomerulosclerosisFollow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study designClinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical TrialEfficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis.Drug discovery in focal and segmental glomerulosclerosisLocal TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.Recent advances in understanding and treating nephrotic syndrome.Pathogenesis and therapy of focal segmental glomerulosclerosis: an update.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.Impact of glomerular kidney diseases on the clearance of drugs.Childhood nephrotic syndrome--current and future therapies.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.Focal Segmental Glomerulosclerosis.Optimal management of primary focal segmental glomerulosclerosis in adultsTLR3-dependent regulation of cytokines in human mesangial cells: a novel role for IP-10 and TNF-alpha in hepatitis C-associated glomerulonephritis.Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.Investigational drugs in development for focal segmental glomerulosclerosis.TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.Deep Learning in Drug Discovery and Medicine; Scratching the Surface
P2860
Q26747770-402FC3AE-9C02-4884-BD84-207B61E8253CQ26753833-5422C598-6CD7-4025-B403-A2F772CAC460Q33527568-6D8DE201-4544-4DEF-A0D8-8F0903AE295BQ33817568-968EE0F4-3884-4F8E-B711-E945EEB6BB9FQ35658566-4725BC82-47D6-458F-A72A-FBCC8D5578AEQ35704498-B245BB5C-8E10-4098-8B09-F37DC4F2BA95Q36789030-03B9E938-86D7-44D9-81A1-A4C1DC97B987Q36924116-C351B223-1944-4FE0-A401-2F065D966B52Q37217446-DDFE79CD-121A-47A2-86A2-BFFEC31F9D25Q37635783-73D30BDB-C5B9-4E06-B8FB-907467655C9CQ37812564-BB876190-8C73-4334-BDAA-63195DF1275EQ37904098-FA622A2F-03C9-4CBD-B47A-4783E2F7CC77Q37974647-45F092B3-4C93-4776-9D49-39471E44B732Q38017937-051DE75D-DD1C-4628-B01F-31CDEB29D672Q38291356-30E507CE-91E2-43CD-B03B-0FF5A069E654Q38531349-DAAA7ECF-8F33-49F7-8AF9-CE50D6023EEEQ38738516-FFEF16BF-9013-4F8B-BD5A-3A64106561EDQ38938623-EC21B31C-C932-4F68-A0A8-2FBADF53BBAFQ39331611-FA651B8A-2875-4B99-8757-85BA6EE0A6BBQ44125808-F35DBA01-2BF4-4097-B2D8-CFAD5D69B32EQ50867897-E69D836A-7255-4B5E-B8BE-BC6766CE17ADQ51840896-A229852E-C7DD-4035-AA3D-F64EEE8824D3Q52624737-1BC66A91-19F1-45BE-926A-9ED15BE0EDA4Q58691544-9D8DDBE4-333D-4CF5-AB82-5D58211EBE41
P2860
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@ast
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@en
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis
@nl
type
label
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@ast
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@en
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis
@nl
prefLabel
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@ast
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@en
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis
@nl
P2093
P2860
P1476
Phase 1 trial of adalimumab in ...... or Resistant FSGS) study group
@en
P2093
Agnes B Fogo
Allison Eddy
Cynthia Pan
Daniel Cattran
Debbie S Gipson
J Charles Jennette
Jacqueline MacHardy
Leslie Powell
Melanie S Joy
Suzanne Vento
P2860
P356
10.1053/J.AJKD.2009.08.019
P577
2009-11-22T00:00:00Z